Advertisement

Cervical Cancer Screening in Pregnancy

  • Dipanwita Banerjee
  • Ranajit Mandal
  • Alpana Chhetri
Chapter

Abstract

Cervical cancer is the most common genital malignancy diagnosed during pregnancy. Around 3% of newly diagnosed invasive cervical cancer occurs in pregnant women. The prevalence of abnormal cytological test result in pregnancy does not differ from the age-matched non-pregnant population. The present guidelines for cervical cancer screening in the pregnant population are not different from those in the non-pregnant population. The screening guidelines are dependent on the severity of abnormality on cytological test report. Due to hormonal changes in the pregnant cervix, interpretation of cytology and visual screening tests becomes difficult. Expectant management can be done in case of human papillomavirus DNA test positive cases until postpartum. In low-grade abnormalities on Papanicolaou smear, visual inspection on acetic acid (VIA) positive and even human papillomavirus DNA test positive cases colposcopy and/or biopsy may be deferred until 6 weeks postpartum. In case of high-grade lesions, biopsy should be performed to rule out invasive cancers. Treatment options are also the same as in non-pregnant women but shall be reserved for highly selected cases and only to rule out invasive cancers. In invasive cancer cases, appropriate referral to the oncology center with a multidisciplinary team approach can influence the obstetric outcome as well as the prognosis of the disease.

Keywords

Cervical cancer screening in pregnancy Management of abnormal Pap smear in pregnancy Pregnancy and CIN Pregnancy and cervical pre-cancers 

References

  1. 1.
    McIntyre-Seltman K, Lesnock JL. Cervical cancer screening in pregnancy. Obstet Gynecol Clin N Am. 2008;35(4):645–58.CrossRefGoogle Scholar
  2. 2.
    Economos D, Perez VN, Delke I, Collado ML, Tancer ML. Abnormal cervical cytology in pregnancy: a 17-year experience. Obstet Gynecol. 1993;81:915–8.PubMedGoogle Scholar
  3. 3.
    WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Summary report on HPV and cervical cancer statistics in India 2012.Google Scholar
  4. 4.
  5. 5.
    Shastri SS, Mittra I, Mishra GA, Gupta S, Dikshit R, Singh S, et al. Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India. J Natl Cancer Inst. 2014;106(3):dju009.  https://doi.org/10.1093/jnci/dju009. Epub 2014 Feb 22CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Mittal S, Ghosh I, Banerjee D, Singh P, Biswas J, Nijhawan R, et al. Reproducibility of cervical intraepithelial neoplasia diagnosis on histological review of cervical punch biopsies from a visual inspection with acetic acid and HPV detection-based screening program. Int J Gynaecol Obstet. 2014;126(3):227–31.  https://doi.org/10.1016/j.ijgo.2014.03.037. Epub 2014 May 29CrossRefPubMedGoogle Scholar
  7. 7.
    Basu P, Mittal S, Banerjee D, Singh P, Panda C, Dutta S, et al. Diagnostic accuracy of VIA and HPV detection as primary and sequential screening tests in a Cervical Cancer Screening Demonstration Project in India. Int J Cancer. 2015;  https://doi.org/10.1002/ijc.29458.CrossRefGoogle Scholar
  8. 8.
    IARC handbook of cancer prevention. Vol. 10. https://www.iarc.fr/en/publications/pdfs-online. Accessed 12 Aug 2017.
  9. 9.
    Bobdey S, Sathwara J, Jain A, Balasubramaniam G. Burden of cervical cancer and role of screening in India. Indian J Med Paediatr Oncol. 2016;37(4):278–85.  https://doi.org/10.4103/0971-5851.195751.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Gravitt PE, Paul P, Katki HA, Vendantham H, Ramakrishna G, Sudula M, et al. Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India. CATCH Study Team. PLoS One. 2010;5(10):e13711.CrossRefGoogle Scholar
  11. 11.
  12. 12.
    Vink MA, Bogaards JA, van Kemenade FJ, de Melker HE, Meijer CJ, Berkhof J. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am J Epidemiol. 2013;178(7):1161–9.CrossRefGoogle Scholar
  13. 13.
    Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin Number 131: screening for cervical cancer. Obstet Gynecol. 2012;120(5):1222–38.Google Scholar
  14. 14.
    Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147–72.  https://doi.org/10.3322/caac.21139.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Moyer VA. U.S. Preventive Services Task Force Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;156:880–91.  https://doi.org/10.7326/0003-4819-156-12-201206190-00424.CrossRefPubMedGoogle Scholar
  16. 16.
  17. 17.
    Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006;24(Suppl 3):S78–89.CrossRefGoogle Scholar
  18. 18.
    Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol. 2010;11:165–73.CrossRefGoogle Scholar
  19. 19.
    Sankaranarayanan R, Chatterji R, Shastri SS, Wesley RS, Basu P, Mahe C, et al. Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicenter study in India. Int J Cancer. 2004;112:341–7.CrossRefGoogle Scholar
  20. 20.
    Manikkam B. Screening for cervical cancer during pregnancy. Int J Commun Med Public Health. 2016;3(9)  https://doi.org/10.18203/2394-6040.ijcmph20163059.
  21. 21.
    Dinc A. Pap smear screening results for Turkish pregnant women. Asian Pac J Cancer Prev. 2012;13(11):5835–8.CrossRefGoogle Scholar
  22. 22.
    Lorincz A, Castanon A, Lim AWW, Sasieni P. New strategies for HPV-based cervical screening. Women’s Health (Lond Engl). 2013;9(5)  https://doi.org/10.2217/whe.13.48.CrossRefGoogle Scholar
  23. 23.
    WHO guidelines: use of cryotherapy for cervical intraepithelial neoplasia. Recommendations. Geneva: World Health Organization; 2011. https://www.ncbi.nlm.nih.gov/books/NBK138474.
  24. 24.
    WHO guidelines. WHO guidelines for screening and treatment of pre-cancerous lesions for cervical cancer prevention. http://apps.who.int/iris/bitstream/10665/94830/1/9789241548694_eng.pdf. Accessed 31 Dec 2017.
  25. 25.
    Kyrgiou M, Mitra A, Arbyn M, Stasinou SM, Martin-Hirsch P, Bennett P, et al. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ. 2014;349:g6192.  https://doi.org/10.1136/bmj.g6192.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Khalid S, Dimitriou E, Conroy R, Paraskevaidis E, Kyrgiou M, Harrity C, et al. The thickness and volume of LLETZ specimens can predict the relative risk of pregnancy-related morbidity. Br J Obstetr Gynaecol. 2012;119:685–91.CrossRefGoogle Scholar
  27. 27.
    Arbyn M, Kyrgiou M, Gondry J, Petry KU, Paraskevaidis E. Long term outcomes for women treated for cervical pre-cancer. BMJ. 2014;348:f7700.CrossRefGoogle Scholar
  28. 28.
    Kyrgiou M, Valasoulis G, Stasinou SM, Founta C, Athanasiou A, Bennett P, et al. Proportion of cervical excision for cervical intraepithelial neoplasia as a predictor of pregnancy outcomes. Int J Gynaecol Obstet. 2015;128(2):141–7.  https://doi.org/10.1016/j.ijgo.2014.07.038. Epub 2014 Oct 2CrossRefPubMedGoogle Scholar
  29. 29.
    Jakobsson M, Gissler M, Sainio S, Paavonen J, Tapper AM. Preterm delivery after surgical treatment for cervical intraepithelial neoplasia. Obstet Gynecol. 2007;109(2 Pt 1):309–13.CrossRefGoogle Scholar
  30. 30.
    Schlichte MJ, Guidry J. Current cervical carcinoma screening guidelines. J Clin Med. 2015;4(5):918–32.  https://doi.org/10.3390/jcm4050918.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Mailath-Pokorny M, Schwameis R, Grimm C, Reinthaller A, Polterauer S. Natural history of cervical intraepithelial neoplasia in pregnancy: postpartum histo-pathologic outcome and review of the literature. BMC Pregnancy Childbirth. 2016;16:74. Published online 2016 Apr 7.  https://doi.org/10.1186/s12884-016-0861-8.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Zhang X, Gao Y, Yang Y. Treatment and prognosis of cervical cancer associated with pregnancy: analysis of 20 cases from a Chinese tumor institution. J Zhejiang Univ Sci B. 2015;16(5):388–94.  https://doi.org/10.1631/jzus.B1400251.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Rossi PG, Carozzi F, Federici A, Ronco G, Zappa M, Franceschi S. Cervical cancer screening in women vaccinated against human papillomavirus infection: recommendations from a consensus conference. Prev Med. 2017;98:21–30.CrossRefGoogle Scholar
  34. 34.
    Herweijer E, Feldman AL, Ploner A, Arnheim-Dahlström L, Uhnoo I, Netterlid E, et al. The participation of HPV-vaccinated women in a national cervical screening program: population-based cohort study. PLoS One. 2015;10(7):e0134185.  https://doi.org/10.1371/journal.pone.0134185.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Dipanwita Banerjee
    • 1
  • Ranajit Mandal
    • 1
  • Alpana Chhetri
    • 2
  1. 1.Department of Gynaecological OncologyChittaranjan National Cancer InstituteKolkataIndia
  2. 2.Department of Obstetrics and GynaecologyChittaranjan Seva Sadan College of Obstetrics, Gynaecology and Child HealthKolkataIndia

Personalised recommendations